Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|FGFR2 - SORBS1 FGFR2 K660M FGFR2 K715R||intrahepatic cholangiocarcinoma||sensitive||Futibatinib||Case Reports/Case Series||Actionable||In a Phase I trial, a patient with intrahepatic cholangiocarcinoma, harboring an FGFR2-SORBS1 fusion with FGFR2 K660M and K175R mutations, responded to TAS-120 for 15.8 months before progressing due to an acquired FGFR2 V565F mutation, detected in cell-free DNA (PMID: 31109923; NCT02052778).||31109923|
|FGFR2 - SORBS1 FGFR2 K660M FGFR2 K715R||intrahepatic cholangiocarcinoma||resistant||Infigratinib||Case Reports/Case Series||Actionable||In a clinical case study, a patient with intrahepatic cholangiocarcinoma harboring an FGFR2-SORBS1 fusion developed progressive disease after initial response to Infigratinib (BGJ398) for 12.6 months and FGFR2 K660M and FGFR2 K715R were identified in the post-progression cell-free DNA (PMID: 31109923).||31109923|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|